Heavy Chain Disease – Mu (Mu-HCD)

Mu heavy chain disease (mu-HCD) is the rarest of the three heavy chain diseases, with approximately 30–40 cases documented in the world medical literature. It is characterized by clonal B-cells or plasma cells that produce truncated mu immunoglobulin heavy chains — the heavy chain isotype associated with IgM — which cannot assemble normally with light chains. Paradoxically, free light chains are produced and appear in the urine as Bence-Jones protein. Clinically, mu-HCD most closely resembles chronic lymphocytic leukemia (CLL), with hepatosplenomegaly and bone marrow infiltration as dominant features. A pathognomonic finding is the presence of vacuolated plasma cells in the bone marrow biopsy.

Mu-HCD typically presents with symptoms related to progressive hepatosplenomegaly — particularly an enlarged spleen causing left-sided abdominal discomfort or fullness. Fatigue and weakness from anemia, easy bruising from thrombocytopenia, and recurrent infections from immunoparesis may also be early features. The clinical picture closely resembles CLL, and mu-HCD is almost always misdiagnosed as CLL or another common B-cell disorder at initial presentation. The diagnosis is typically established only after specific immunofixation testing with anti-mu antisera is performed.

In mu-HCD, the clonal B-cells or plasma cells produce both truncated mu heavy chains AND free light chains — but the structural defect in the truncated mu heavy chain prevents normal assembly with light chains into a complete immunoglobulin molecule. The excess, unassembled free light chains are then excreted in the urine as Bence-Jones protein. This is paradoxical because typical heavy chain diseases (alpha and gamma) do not produce urinary light chains. Bence-Jones proteinuria in mu-HCD is an important diagnostic clue and also raises concern for light chain-related renal tubular damage over time.

Diagnosis requires three key findings: (1) truncated mu heavy chain protein detected on serum immunofixation using anti-mu specific antisera — without associated light chain reactivity; (2) free light chains (Bence-Jones protein) detected in urine by immunofixation; and (3) bone marrow biopsy showing characteristic vacuolated plasma cells. This diagnostic triad, while rare, is specific for mu-HCD. Expert hematopathology review is essential given that routine SPEP may not show a clear M-spike and anti-mu antisera testing may not be performed in standard protein evaluation panels.

No standardized treatment protocol exists for mu-HCD due to its extreme rarity. Treatment is individualized based on disease burden and clinical presentation. Asymptomatic patients may be monitored without immediate treatment. For progressive or symptomatic disease, CLL-directed approaches have historically been applied, including alkylating agents (chlorambucil, cyclophosphamide) and CHOP chemotherapy. Modern targeted therapies active in CLL — BTK inhibitors (ibrutinib, zanubrutinib) or venetoclax — represent the most rational contemporary approach, though formal evidence is limited to case reports. Rituximab may be added if CD20 is expressed. Splenectomy may be considered for massive symptomatic splenomegaly.

Vacuolated plasma cells in the bone marrow biopsy are considered a pathognomonic — uniquely characteristic — finding of mu-HCD. The cytoplasmic vacuoles represent accumulation of the truncated mu heavy chain protein within plasma cells that cannot be secreted normally due to the structural defect in the heavy chain. When a bone marrow biopsy shows vacuolated plasma cells alongside a CLL-like lymphocytic infiltrate, specific immunofixation testing for mu heavy chains should be performed to exclude mu-HCD. This morphologic feature is not found in CLL, myeloma, or lymphoplasmacytic lymphoma.

Mu-HCD closely resembles CLL clinically — with hepatosplenomegaly, bone marrow infiltration, and modest lymphocytosis. However, it is a distinct entity: the malignant clone secretes truncated mu heavy chains (not IgM or IgG as in CLL), and the bone marrow contains vacuolated plasma cells not seen in CLL. While myeloma produces monoclonal immunoglobulin and may show Bence-Jones proteinuria, myeloma is defined by lytic bone disease, hypercalcemia, and a different immunophenotype. Mu-HCD shares features of both conditions but is biologically distinct from each.

Yes — prolonged Bence-Jones proteinuria in mu-HCD can cause light chain-related renal damage, most commonly proximal tubular dysfunction (Fanconi syndrome), where the renal tubules lose the ability to reabsorb glucose, amino acids, phosphate, and other solutes. Cast nephropathy (myeloma kidney) is less common but possible. Regular monitoring of renal function, urine protein quantification, and assessment for tubular dysfunction markers is important throughout the disease course and should be part of routine follow-up.

Yes. Given that mu-HCD is one of the rarest hematologic conditions on record, CancerFax's role in connecting patients to specialist expertise is particularly valuable. CancerFax can facilitate medical report review by hematopathologists familiar with rare lymphoproliferative disorders, coordinate second opinions at centers with rare hematology expertise, assist with identifying clinical trials in related conditions (CLL, lymphoplasmacytic lymphoma, rare B-cell disease) where mu-HCD patients may be eligible, and provide coordination support for accessing specialist care internationally — including leading hematology programs in India, China, Europe, and the United States.